Wallace Woon and Jong Ching Yee

Efforts to come up with new treatments for patients suffering from osteoarthritis have been boosted by a $1.2 million donation from local biotechnology company StemGen Therapeutics to the Lee Kong Chian School of Medicine (LKCMedicine).

The joint disorder affects many elderly people and Singapore has an increasingly ageing population. The Government will match the donation in a contribution to the LKCMedicine Endowment Fund.

Speaking at the signing ceremony for the StemGen-LKCMedicine Regenerative Medicine Research Fund yesterday, National Healthcare Group deputy chief executive of education and research Benjamin Seet said the fund will support research in stem cell technology and regenerative medicine that focuses on developing therapy methods for patients suffering from osteoarthritis of the knee.

“Despite (osteoarthritis) being a highly prevalent disease that affects up to 80 per cent of people aged 65 years and older, as well as a leading cause of physical disability in the elderly, there is currently no effective treatment to stop (its) progression,” he said.

Current methods to treat the disease comprise symptomatic pain relief, steroid injections to reduce inflammation, and knee surgery, said Professor Seet.

“With Singapore’s rapidly ageing population, osteoarthritis has become a major cause of morbidity and disability here.”

StemGen chief executive James Hsieh said the fund will also help support the training of qualified regenerative medicine scientists and practitioners.

“Stem cell therapy has tremendous potential to revolutionise healthcare in Singapore,” he said.

“The creation of the StemGen-LKCMedicine Regenerative Medicine Research Fund will be a first step to develop the know-how and technologies to manufacture and administer stem cell therapies safely, effectively and affordably.”

“Leveraging the university’s strengths in engineering and bio-medical research, and LKCMedicine’s focus on translational research, the gift will go towards developing innovative tools and therapies that will be beneficial for patients,” said Professor Sund.

The donation is the most recent of monetary injections that LKCMedicine has received for stem cell and regenerative medicine research, said an NTU spokesman, adding that grants of $10 million had been received in each of the past two years.

Professor Sund said he is looking forward to the close collaboration between LKCMedicine and its clinical and industrial partners.

“With our partners, we have taken confident steps towards finding disruptive discoveries to help our ageing population leading to better lives.”

$1.2m boost for research on treatments for joint disorder

Fund focusing on osteoarthritis of the knee comes as Singapore population grows older

Wallace Woon
and Jong Ching Yee

Efforts to come up with new treatments for patients suffering from osteoarthritis have been boosted by a $1.2 million donation from local biotechnology company StemGen Therapeutics to the Lee Kong Chian School of Medicine (LKCMedicine).

The joint disorder affects many elderly people and Singapore has an increasingly ageing population. The Government will match the donation in a contribution to the LKCMedicine Endowment Fund.

Speaking at the signing ceremony for the StemGen-LKCMedicine Regenerative Medicine Research Fund yesterday, National Healthcare Group deputy chief executive of education and research Benjamin Seet said the fund will support research in stem cell technology and regenerative medicine that focuses on developing therapy methods for patients suffering from osteoarthritis of the knee.

“Despite (osteoarthritis) being a highly prevalent disease that affects up to 80 per cent of people aged 65 years and older, as well as a leading cause of physical disability in the elderly, there is currently no effective treatment to stop (its) progression,” he said.

Current methods to treat the disease comprise symptomatic pain relief, steroid injections to reduce inflammation, and knee surgery, said Professor Seet.

“With Singapore’s rapidly ageing population, osteoarthritis has become a major cause of morbidity and disability here.”

StemGen chief executive James Hsieh said the fund will also help support the training of qualified regenerative medicine scientists and practitioners.

“Stem cell therapy has tremendous potential to revolutionise healthcare in Singapore,” he said.

“The creation of the StemGen-LKCMedicine Regenerative Medicine Research Fund will be a first step to develop the know-how and technologies to manufacture and administer stem cell therapies safely, effectively and affordably.”

Prof Seet identified two projects that will be beneficiaries of the fund. One aims to develop a 3D-printed, stem cell-loaded bone graft, while the other is seeking to develop medicine that could help osteoarthritis patients regenerate the cartilage around their joints.

LKCMedicine dean Joseph Sung said Nanyang Technological University (NTU) – which the medical school is a part of – will be able to bring together the diverse mix of scientists required for highly interdisciplinary research in fields like regenerative medicine.

“The donation is the most recent of monetary injections that LKCMedicine has received for stem cell and regenerative medicine research, said an NTU spokesman, adding that grants of $10 million had been received in each of the past two years.

Professor Sund said he is looking forward to the close collaboration between LKCMedicine and its clinical and industrial partners.

“With our partners, we have taken confident steps towards finding disruptive discoveries to help our ageing population leading to better lives.”

wallacewoon@sph.com.sg
jongchingyee@sph.com.sg